Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency

• Published in: Future medicinal chemistry Vol. 11; no. 16; pp. 2131 - 2150
• Main Authors: Lin, Ming-Hsien, Hung, Chi-Feng, Hsu, Ching-Yun, Lin, Zih-Chan, Fang, Jia-You
• Format: Journal Article
• Language: English
• Published: England Newlands Press Ltd 01.08.2019; Newlands Press
• Subjects: anticancer therapy; Antitumor agents; Bioavailability; Biodegradation; conjugation; drug delivery; Drug therapy; Efficiency; Enzymes; Metabolism; nanoparticle; Nanoparticles; Nanotechnology; Permeability; prodrug; Prodrugs; Quantum dots; Tumor cells; prodrug; anticancer therapy; nanoparticle; drug delivery; conjugation
• ISSN: 1756-8919; 1756-8927
• DOI: 10.4155/fmc-2018-0388

Prodrug entrapment into nanocarriers for tumor delivery is a strategy to achieve a valid therapy with high efficiency. The prodrug contains anticancer agents conjugating with functional moieties or ligands so that the active component is released after metabolism in the body or tumor. The advantages of nanosystems for loading prodrugs include high loading, increased prodrug stability, improved bioavailability and enhanced targeting to tumor cells. In the present article, we introduce the prodrug delivery approaches according to nanomedicine and the recent advances in prodrug-loaded nanocarriers. First, we discuss the conceptional design of combined prodrugs and nanocarriers in response to the obstruction in anticancer therapy. Then we describe the cases of prodrug-loaded nanoparticles for cancer treatment during the past 5 years.